{"entity":{"id":"hemiasterlin-payloads","kind":"term","name":"Hemiasterlin payloads","aka":["SC209","tazevibulin payload","3-aminophenyl hemiasterlin","SC239 linker-payload"],"tldr":"Hemiasterlin-derived payloads disrupt the scaffolding used in cell division. One is carried by the experimental antibody drug luveltamab tazevibulin.","summary":"Luveltamab tazevibulin, or STRO-002, uses the folate receptor alpha antibody to deliver the tubulin-targeting hemiasterlin derivative SC209. SC239 is the linker-warhead used to assemble the conjugate, not a synonym for the released SC209 alone. The primary discovery study reported antigen-dependent killing, bystander activity and efficacy in xenograft models. This is a different scaffold within the tubulin class, not a mechanism unrelated to tubulin.","asOf":"2026-11-08","links":[{"label":"Discovery of STRO-002 and its hemiasterlin payload (2023)","url":"https://doi.org/10.1158/1535-7163.MCT-22-0322"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["adc"],"targets":[],"drugs":["luveltamab-tazevibulin"],"companies":[],"institutions":[],"pathways":[],"terms":["payload","tubulin-inhibitor-payloads"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"category":"ADC chemistry"},"route":"/terms/hemiasterlin-payloads/","neighbours":{"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"}],"drug":[{"id":"luveltamab-tazevibulin","kind":"drug","name":"Luveltamab tazevibulin","route":"/drugs/luveltamab-tazevibulin/"}],"term":[{"id":"next-generation-adc-payloads","kind":"term","name":"Next-generation antibody-conjugate payloads","route":"/terms/next-generation-adc-payloads/"},{"id":"payload","kind":"term","name":"Payload (ADC)","route":"/terms/payload/"},{"id":"tubulin-inhibitor-payloads","kind":"term","name":"Tubulin inhibitor payloads","route":"/terms/tubulin-inhibitor-payloads/"}]}}